Bicycle Therapeutics plc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Bicycle Therapeutics plc | BCYC - NASDAQ |
$14.00-$16.00 | $14.00 | $13.37 | 4.33 million | 5/23/2019 |
| Goldman Sachs, Jefferies, Piper Jaffray | ||||||
Co-Manager(s): Canaccord Genuity | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-04-26 Terms Added 2019-05-13 | ||||||
Bicycle Therapeutics plc Quote & Chart - Click for current quote - BCYC
IPO Boutique aggregates information on public companies and private companies, such as "BCYC" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Bicycle Therapeutics plc (adapted from Bicycle Therapeutics plc prospectus):
They are a clinical-stage biopharmaceutical company developing a novel class of medicines, which we refer to as Bicycles, for diseases that are underserved by existing therapeutics.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing a novel class of medicines, which we refer to as Bicycles, for diseases that are underserved by existing therapeutics.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BCYC" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.